Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Neostigmine Methyl Sulfate

            Therapeutic Area: Musculoskeletal Product Name: Bloxiverz

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Exela Pharma Sciences, LLC.

            Deal Size: $42.0 million Upfront Cash: $14.5 million

            Deal Type: Divestment July 01, 2020


            Company announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz®, Vazculep®, and Akovaz®, as well as Nouress™ o Exela Sterile Medicines LLC.